New combo therapy targets Hard-to-Treat lymphomas

NCT ID NCT01695941

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times

Summary

This early-phase study tests a combination of three drugs (alisertib, bortezomib, and rituximab) in adults with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to treatment. The main goal is to find the safest dose and check for side effects. Researchers also track how well the tumors shrink and how long patients stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York, 10016, United States

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, 10461, United States

Conditions

Explore the condition pages connected to this study.